MX2009003921A - Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b. - Google Patents
Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b.Info
- Publication number
- MX2009003921A MX2009003921A MX2009003921A MX2009003921A MX2009003921A MX 2009003921 A MX2009003921 A MX 2009003921A MX 2009003921 A MX2009003921 A MX 2009003921A MX 2009003921 A MX2009003921 A MX 2009003921A MX 2009003921 A MX2009003921 A MX 2009003921A
- Authority
- MX
- Mexico
- Prior art keywords
- reduction
- omega
- levels
- fatty acids
- apo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85028006P | 2006-10-10 | 2006-10-10 | |
PCT/US2007/021631 WO2008045465A1 (en) | 2006-10-10 | 2007-10-10 | Omega-3 fatty acids and dyslipidemic agent for reduction of apo-b levels |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009003921A true MX2009003921A (es) | 2009-08-31 |
Family
ID=39283166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009003921A MX2009003921A (es) | 2006-10-10 | 2007-10-10 | Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2089014A4 (zh) |
JP (1) | JP2010505956A (zh) |
KR (1) | KR20090080070A (zh) |
CN (2) | CN101553221A (zh) |
AU (1) | AU2007307007A1 (zh) |
BR (1) | BRPI0719182A2 (zh) |
CA (1) | CA2672919A1 (zh) |
EA (2) | EA018734B1 (zh) |
MX (1) | MX2009003921A (zh) |
WO (1) | WO2008045465A1 (zh) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
WO2008088415A1 (en) * | 2006-10-18 | 2008-07-24 | Reliant Pharmaceuticals, Inc. | Omega-3 fatty acids for reduction of lp-pla2 levels |
EP4137128A1 (en) | 2008-09-02 | 2023-02-22 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same |
PT2395991E (pt) | 2009-02-10 | 2013-09-03 | Amarin Pharmaceuticals Ie Ltd | Utilização de éster etílico de ácido eicosapentaenóico para tratamento de hipertrigliceridemia |
EP3791880A1 (en) | 2009-04-29 | 2021-03-17 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa |
LT3278665T (lt) | 2009-04-29 | 2020-12-10 | Amarin Pharmaceuticals Ireland Limited | Stabili farmacinė kompozicija ir jos panaudojimo būdai |
ES2856959T3 (es) * | 2009-06-15 | 2021-09-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para el tratamiento del ictus en un sujeto en terapia simultánea con estatina |
RU2012116079A (ru) | 2009-09-23 | 2013-10-27 | АМАРИН КОРПОРЕЙШН ПиЭлСи | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения |
US20140127289A1 (en) | 2010-11-29 | 2014-05-08 | Armarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
DK3363433T3 (da) | 2012-06-29 | 2021-03-08 | Amarin Pharmaceuticals Ie Ltd | Fremgangsmåder til reduktion af risikoen for en kardiovaskulær begivenhed i et individ i statinbehandling ved anvendelse af eicosapentaensyreetylester |
CN102824636A (zh) * | 2012-08-15 | 2012-12-19 | 四川大学 | 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途 |
JP6227535B2 (ja) * | 2012-08-30 | 2017-11-08 | 株式会社三和化学研究所 | 脂質異常症の予防又は治療薬 |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
MA39319A1 (fr) * | 2014-02-05 | 2017-07-31 | Mitsubishi Tanabe Pharma Corp | Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
PT4056176T (pt) | 2018-09-24 | 2024-05-27 | Amarin Pharmaceuticals Ie Ltd | Métodos de redução do risco de eventos cardiovasculares num indivíduo |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030170643A1 (en) * | 1999-10-26 | 2003-09-11 | Edward Fisher | Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
EP1830830A4 (en) * | 2004-12-06 | 2010-02-10 | Reliant Pharmaceuticals Inc | OMEGA-3 FATTY ACIDS AND DYSLIPIDEMIC MEANS FOR LIPID THERAPY |
KR20080037674A (ko) * | 2005-07-18 | 2008-04-30 | 릴라이언트 파마슈티컬스 인코퍼레이티드 | 아제티디논계 콜레스테롤 흡수 억제제 및 오메가-3 지방산및 이들의 조합물로의 치료 |
-
2007
- 2007-09-07 EA EA200970359A patent/EA018734B1/ru not_active IP Right Cessation
- 2007-09-07 CN CNA2007800456489A patent/CN101553221A/zh active Pending
- 2007-10-10 CN CNA2007800456667A patent/CN101553220A/zh active Pending
- 2007-10-10 BR BRPI0719182-0A2A patent/BRPI0719182A2/pt not_active Application Discontinuation
- 2007-10-10 CA CA002672919A patent/CA2672919A1/en not_active Abandoned
- 2007-10-10 EA EA200970360A patent/EA200970360A1/ru unknown
- 2007-10-10 EP EP07852630A patent/EP2089014A4/en not_active Withdrawn
- 2007-10-10 KR KR1020097009523A patent/KR20090080070A/ko not_active Application Discontinuation
- 2007-10-10 AU AU2007307007A patent/AU2007307007A1/en not_active Abandoned
- 2007-10-10 JP JP2009532391A patent/JP2010505956A/ja active Pending
- 2007-10-10 MX MX2009003921A patent/MX2009003921A/es unknown
- 2007-10-10 WO PCT/US2007/021631 patent/WO2008045465A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA2672919A1 (en) | 2008-04-17 |
CN101553220A (zh) | 2009-10-07 |
CN101553221A (zh) | 2009-10-07 |
EA018734B1 (ru) | 2013-10-30 |
EP2089014A4 (en) | 2009-12-09 |
AU2007307007A1 (en) | 2008-04-17 |
EP2089014A1 (en) | 2009-08-19 |
WO2008045465A1 (en) | 2008-04-17 |
BRPI0719182A2 (pt) | 2014-10-21 |
EA200970360A1 (ru) | 2009-10-30 |
KR20090080070A (ko) | 2009-07-23 |
EA200970359A1 (ru) | 2009-10-30 |
JP2010505956A (ja) | 2010-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009003921A (es) | Acidos grasos omega-3 y agente dislipidemico para la reduccion de los niveles de apo-b. | |
MX2009003920A (es) | Estatina y acidos grasos omega 3 para reducir los niveles de apo b. | |
WO2006062748A3 (en) | Omega-3 fatty acids and dyslipidemic agent for lipid therapy | |
EP2014292A3 (en) | Fenoldopam for treatment of acute renal failure | |
WO2008088415A8 (en) | Omega-3 fatty acids for reduction of lp-pla2 levels | |
EP2392363A3 (en) | Drug coated expandable devices | |
NZ541593A (en) | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis | |
BR0312933A (pt) | Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica | |
JP2007523049A5 (zh) | ||
MX2007011031A (es) | Tratamiento con estatina y acidos grasos omega-3 y un producto de combinacion de los mismos. | |
WO2007002572A3 (en) | Nattokinase for reducing whole blood viscosity | |
WO2003072024A3 (en) | Methods of treating vascular disease | |
MY138301A (en) | The use of substituted azetidinone compounds for the treatment of sitosterolemia | |
EP1658849A3 (en) | therapeutic combinations of antihypertensive and antiangiogenic agents | |
GB0410266D0 (en) | Treatment of apoptosis | |
EE200100405A (et) | 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks | |
CA2534202A1 (en) | Lipid glycerides for the treatment of neurodegenerative conditions involving demyelination | |
JP2005511619A5 (zh) | ||
AU2003291536A1 (en) | Method for the diagnosis and treatment of vascular disease | |
WO2005058280A3 (en) | Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure | |
WO2006109170A3 (en) | Combination therapy for treatment of cardiovascular diseases and related conditions | |
PL368572A1 (en) | Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections | |
MX291518B (es) | Acidos grasos esenciales en la prevencion y/o el tratamiento de depresion en pacientes con enfermedad cardiaca coronarias o arterial coronaria. | |
HUP0301451A3 (en) | Use of cgmp pde5 inhibitors for the preparation of pharmaceutical compositions treating peripheral vascular diseases, peripheral neuropathies and autonomic neuropathies | |
WO2008079818A3 (en) | Intravenous administration of water soluble analgesic formulations |